AR018010A1 - Secretagogos de la hormona del crecimiento y compuestos intermediarios utiles en la preparacion de dichos compuestos - Google Patents

Secretagogos de la hormona del crecimiento y compuestos intermediarios utiles en la preparacion de dichos compuestos

Info

Publication number
AR018010A1
AR018010A1 ARP980104068A ARP980104068A AR018010A1 AR 018010 A1 AR018010 A1 AR 018010A1 AR P980104068 A ARP980104068 A AR P980104068A AR P980104068 A ARP980104068 A AR P980104068A AR 018010 A1 AR018010 A1 AR 018010A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
cyclohexyl
alkylidenyl
nhr1
Prior art date
Application number
ARP980104068A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR018010A1 publication Critical patent/AR018010A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/42—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se trata de compuestos no péptidos denominados genéricamente secretagogos que poseen actividad secretora de la hormona del crecimiento de formula (I) en laque: A es alquilo C1-6, arilo, (alquil C1-6)arilo, (alquil C1-6)(O)(alquil C1-6)arilo, -SH, -OH, indolilo, indolinilo, tienilo, benzotienilo, benzofuranilo,naftanilo, ciclohexilo, (alquil C1-6)indol-3-ilo, (alquil C1-6)benzotien-3-ilo, (alquil C1-6)naftan-2-ilo, (alquil C1-6)benzofuran-3-ilo y (alquil C1-6)ciclohexilo; B es NH2, NHR1, (alquilC1-6)-NH2, (alquil C1-6)-NHR1, (alquil C1-6)aril-NH2, (alquil C1-6)aril-NR1, (alquil C1-6)ciclohexil NH2, (alquil C1-6)ciclohexil NHR1, R1-piperidin-3-il,(alquil C1-6), R1-piperidin-2-il, (alquil C1-6), R1-piperidin-4-il (alquil C1-6), R1-quinolin-2-il,(alquil C1-6),R1-(2,4-dihidroquinolin-2-il,(alquil C1-6),R1-isoquinolin-2-il, (alquil C1-6) y R1-(2,4-dihidroisoquinolin-2-il), (alquil C1-6); R1 es hidrogeno,alquilo C1-6 (alquilC1-6)OH o (alquilidenil C1-6)(OH); R2 es alquilo C1-6 alquenilo C1-6(alquil C1-6)(O)(alquilo C1-6), C(O)-O-alquilo C1-6, arilo o (alquil C1-6)arilo; X es unenlace, alquilidenilo C1-6 O, S, NH o N(alquilo C1-6); V es un grupo de formulas (I), W es S. O, NH o CH2; Y es N o Ch; Z es N o CH; Y es N, S, CH2, O; Z esN, CH2; R4 y R5 son, de forma independiente, hidrogeno, alquilo C1-6, arilo, (alquil C1-C6)arilo, C(O)O(alquilo C1-6), C(O)ON(alquilo C1-6)2 o (alquil C1-6)COR7; R7 es hidrogeno, alquilo C1-6, pirrolidinilo, peperidinilo, homoprolina o prolina; D es C(O)R6, (alquil C1-6)OH, (alquil C1-6)C(O)R6, (alquil C1-6)R6,arilo, CH2NHSO2(alquilo C1-6), R6 es H, alquilo C1-6, arilo, (alquil C1-6)arilo, acetilo, NH2, NH(alquilo C1-6), NH(alquilidenil C1-6)OCH3, NH(alquil C1-6)arilo, N(alquilo C1-6)2, N(alquil C1-6)arilo, N(alquil C1-6)(alquil C1-6)arilo, O(alquilo C1-6), piperidinilo o piperidinilo opcionalmente sustituido,pirrolidinilo o pirrolidinilo opcionalmente sustituido, pirrolinilo o pirrolinilo opcionalmente sustituido, morfolino, hexametilenimino, heptametilenimino,quinolinilo, 2,4-dihidroquinolinilo, isoquinolinilo, 2,4-dihidroisoquinolinilo, un aminoácido seleccionado entre el grupo de prolina, homoprolina, glicina,
ARP980104068A 1997-08-19 1998-08-18 Secretagogos de la hormona del crecimiento y compuestos intermediarios utiles en la preparacion de dichos compuestos AR018010A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5614297P 1997-08-19 1997-08-19

Publications (1)

Publication Number Publication Date
AR018010A1 true AR018010A1 (es) 2001-10-31

Family

ID=22002443

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104068A AR018010A1 (es) 1997-08-19 1998-08-18 Secretagogos de la hormona del crecimiento y compuestos intermediarios utiles en la preparacion de dichos compuestos

Country Status (24)

Country Link
EP (1) EP0933365A3 (es)
JP (1) JP2001515046A (es)
KR (1) KR20010027947A (es)
CN (1) CN1243567C (es)
AR (1) AR018010A1 (es)
AU (1) AU738204B2 (es)
BR (1) BR9811948A (es)
CA (1) CA2302467A1 (es)
CO (1) CO5121066A1 (es)
EA (1) EA002746B1 (es)
HR (1) HRP20000090A2 (es)
HU (1) HUP0002392A3 (es)
ID (1) ID25000A (es)
IL (1) IL134596A0 (es)
MY (1) MY138258A (es)
NO (1) NO20000823L (es)
NZ (1) NZ502947A (es)
PE (1) PE115999A1 (es)
PL (1) PL338883A1 (es)
TR (1) TR200000930T2 (es)
TW (1) TW577879B (es)
UA (1) UA58472C2 (es)
WO (1) WO1999008699A1 (es)
ZA (1) ZA987385B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
AU2686899A (en) * 1998-08-18 2000-03-14 Eli Lilly And Company Growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
CO5160260A1 (es) * 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
US6417397B1 (en) 1999-10-04 2002-07-09 The Regents Of The University Of California, San Diego N-substituted alkylamino acids for use as amino-protecting groups
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
US6756385B2 (en) * 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
AU2001294532A1 (en) * 2000-10-13 2002-04-29 Eli Lilly And Company Resolution process for preparation of substantially pure (r) and (s) enantiomersof 2-(4-nitroimidazolyl)-4-methoxyphenylpropionic acid and salts thereof
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
DE60306636T2 (de) 2002-04-09 2007-07-05 Eli Lilly And Co., Indianapolis Wachstumhormonsekretionsförderer
US7365082B2 (en) * 2002-12-18 2008-04-29 Bayer Cropscience Ag N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines
CN1934091B (zh) 2004-03-23 2012-02-08 辉瑞产品公司 治疗神经变性障碍的咪唑化合物
JP2009508934A (ja) 2005-09-22 2009-03-05 ファイザー・プロダクツ・インク 神経障害治療のためのイミダゾール化合物
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
PL3022202T3 (pl) 2013-07-18 2019-10-31 Novartis Ag Inhibitory autotaksyny zawierające heteroaromatyczny rdzeń pierścienia benzylowego - cyklicznego amidu
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
RU2692774C2 (ru) 2014-08-29 2019-06-27 Дайсел Корпорэйшн Имидазольное соединение, жидкость для обработки металлической поверхности, способ обработки металлической поверхности и способ изготовления ламината
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN107286041A (zh) * 2016-04-01 2017-10-24 成都川科化工有限公司 一种n,n-二乙基甲酰胺的制备方法
CN108299218A (zh) * 2017-01-12 2018-07-20 南京红杉生物科技有限公司 一种4-溴-d-苯丙氨酸的合成方法
CN110128285B (zh) * 2019-06-24 2022-03-01 华北制药股份有限公司 D-苯甘氨酸甲酯盐酸盐/d-二氢苯基甘氨酸甲酯盐酸盐的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
WO1994013696A1 (en) * 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
PL314003A1 (en) * 1993-10-19 1996-08-05 Merck & Co Inc Combination of bisulphonates and substances enhancing secretion of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
ZA966891B (en) * 1995-08-21 1998-02-16 Lilly Co Eli 2-acylaminopropanamines as growth hormone secretagogues.
WO1997006803A1 (en) * 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues

Also Published As

Publication number Publication date
MY138258A (en) 2009-05-29
CO5121066A1 (es) 2002-01-30
CN1276727A (zh) 2000-12-13
KR20010027947A (ko) 2001-04-06
HRP20000090A2 (en) 2001-04-30
NO20000823D0 (no) 2000-02-18
TW577879B (en) 2004-03-01
NZ502947A (en) 2001-11-30
AU738204B2 (en) 2001-09-13
CA2302467A1 (en) 1999-02-25
AU9025698A (en) 1999-03-08
ZA987385B (en) 2000-04-18
NO20000823L (no) 2000-04-12
HUP0002392A3 (en) 2000-11-28
HUP0002392A2 (hu) 2000-10-28
EP0933365A3 (en) 2003-03-19
JP2001515046A (ja) 2001-09-18
PE115999A1 (es) 1999-11-26
CN1243567C (zh) 2006-03-01
BR9811948A (pt) 2000-08-22
TR200000930T2 (tr) 2000-11-21
IL134596A0 (en) 2001-04-30
UA58472C2 (uk) 2003-08-15
PL338883A1 (en) 2000-11-20
EA002746B1 (ru) 2002-08-29
EP0933365A2 (en) 1999-08-04
EA200000239A1 (ru) 2000-10-30
ID25000A (id) 2000-09-07
WO1999008699A1 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
AR018010A1 (es) Secretagogos de la hormona del crecimiento y compuestos intermediarios utiles en la preparacion de dichos compuestos
PE107898A1 (es) Compuestos 1,3-diheterociclicos, inhibidores de metaloproteasa
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
DE69728768D1 (de) 2,4-diaminopyrimidine derivates als dopamine d4 rezeptorantagonisten
ES2188184T3 (es) Compuestos de beta-carbolinas.
UY27699A1 (es) Inhibidores.
AR012781A1 (es) Alfa-cetoamida inhibidores de 20s proteosoma.
AR035804A1 (es) Inhibidores novedosos de tirosina cinasa
PE20011233A1 (es) Compuestos alquil aminoazepan-3-ona como inhibidores de proteasas
DE3784799D1 (de) Malonsaeurederivate und ihre synthesemethoden.
DE60209458D1 (de) Verfahren zur Synthese von (2S,3aS,7aS)-1-(S)-Alanyl-octahydro-1H-2-carbonsäurederivaten und Verwendung in der Synthese von Perindopril
ES2061714T3 (es) Grupos de anclaje inestables frente a acidos para la sintesis de amidas peptidicas mediante el metodo en fase solida.
TR200000398T2 (tr) Hepatit B virüsü (HBV) retroviral ters transkriptaz ve DNA polimeraz inhibe edicilerini içeren antiviraller gibi nükleozidlerin analogları.
DK399386A (da) Indolinonderivater, deres fremstilling og anvendelse som laegemidler
PE20001241A1 (es) Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
AR021970A1 (es) Inhibidores de proteasas
KR950702978A (ko) 아미드 유도체(Amide derivatives)
ES2073847T3 (es) Derivados del 2,3,3a,4,5,9b-hexahidro-1h-benzo(e)indol.
ES2744849T3 (es) Hidrogenación catalítica para la preparación de aminas a partir de amidas de ácido carboxílico, diamidas de ácido carboxílico, di-, tri- o polipéptidos o amidas de péptido
ATE178063T1 (de) Zyklische harnstoffe mit antiarrhythmischer und antifibrillatorischer wirkung
ES2191852T3 (es) Procedimiento para producir derivados de depsipeptido y sus nuevos intermedios.
AR018960A1 (es) Compuestos derivados de isoquinolina, composiciones farmaceuticas, su uso en la fabricacion de medicamentos, procedimiento de tratamiento depreparacion y compuestos utiles como intermediarios
BR0009548A (pt) 3-bicicloaril-2-aminometil bicicloalcanos como inibidores da recaptação de serotonina
MASUI et al. Acylation of amines and alcohols by anodic oxidation of N-phenyl-hydroxamic acids
EP0911336A4 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure